Lineage Cell Therapeutics, Inc.: 10-Q filed 2012-11-09

Name: Lineage Cell Therapeutics, Inc.: 10-Q filed 2012-11-09
Creator: Lineage Cell Therapeutics, Inc.

What Lineage Cell Therapeutics, Inc. reported in its quarterly report filed 2012-11-09 (fiscal Q3 2012): 38 published measures, 98 facts as tagged in accession 0001140361-12-046522.

This filing

Form: 10-Q (quarterly report)
Filed: 2012-11-09
Fiscal period: fiscal Q3 2012
Accession: 0001140361-12-046522 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All Lineage Cell Therapeutics, Inc. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

Period	Value	Unit	Days
At 2012-09-30	32,870,336	USD
At 2011-12-31	45,829,695	USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

Period	Value	Unit	Days
At 2012-09-30	16,939,959	USD
At 2011-12-31	28,646,001	USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

Period	Value	Unit
At 2012-09-30	7,830,347	USD
At 2011-12-31	22,211,897	USD
At 2011-09-30	26,230,298	USD
At 2010-12-31	33,324,924	USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

Period	Value	Unit	Days
2012-07-01 to 2012-09-30	-4,958,014	USD	92
2012-01-01 to 2012-09-30	-15,390,749	USD	274
2011-07-01 to 2011-09-30	-3,737,626	USD	92
2011-01-01 to 2011-09-30	-11,154,849	USD	273

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

Period	Value	Unit	Days
2012-01-01 to 2012-09-30	-14,683,440	USD	274
2011-01-01 to 2011-09-30	-9,748,300	USD	273

Capital expenditure payments

Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.

Period	Value	Unit	Days
2012-01-01 to 2012-09-30	205,135	USD	274
2011-01-01 to 2011-09-30	780,524	USD	273

Revenue

Revenue under this specific accounting concept. A missing value is not zero; filers can use other revenue concepts.

Period	Value	Unit	Days
2012-07-01 to 2012-09-30	1,003,551	USD	92
2012-01-01 to 2012-09-30	2,692,790	USD	274
2011-07-01 to 2011-09-30	1,161,570	USD	92
2011-01-01 to 2011-09-30	2,782,439	USD	273

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

Period	Value	Unit	Days
2012-01-01 to 2012-09-30	286,552	USD	274
2011-01-01 to 2011-09-30	3,861,681	USD	273

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

Period	Value	Unit	Days
2012-01-01 to 2012-09-30	91,223	USD	274
2011-01-01 to 2011-09-30	-1,022,716	USD	273

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

Period	Value	Unit	Days
At 2012-09-30	-95,860,758	USD
At 2011-12-31	-80,470,009	USD

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

Period	Value	Unit	Days
At 2012-09-30	1,251,083	USD
At 2011-12-31	1,347,779	USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

Period	Value	Unit	Days
2012-01-01 to 2012-09-30	986,769	USD	274
2011-01-01 to 2011-09-30	828,395	USD	273

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

Period	Value	Unit	Days
2012-07-01 to 2012-09-30	-5,946,558	USD	92
2012-01-01 to 2012-09-30	-17,942,343	USD	274
2011-07-01 to 2011-09-30	-4,232,365	USD	92
2011-01-01 to 2011-09-30	-13,226,195	USD	273

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

Period	Value	Unit	Days
At 2012-09-30	9,748,722	USD
At 2011-12-31	24,955,374	USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

Period	Value	Unit	Days
At 2012-09-30	2,572,803	USD
At 2011-12-31	3,146,655	USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

Period	Value	Unit	Days
At 2012-09-30	708,961	USD
At 2011-12-31	1,118,112	USD

Net finite-lived intangible assets

Finite-lived intangible assets after amortization. This excludes goodwill and should not be combined with indefinite-lived intangible assets without checking scope.

Period	Value	Unit	Days
At 2012-09-30	21,089,661	USD
At 2011-12-31	18,619,516	USD

Net current accounts receivable

Current customer receivables after the allowance for credit loss. The balance is not cash collected or a guarantee of collection.

Period	Value	Unit	Days
At 2012-09-30	891,000	USD
At 2011-12-31	353,000	USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

Period	Value	Unit	Days
2012-07-01 to 2012-09-30	6,780,375	USD	92
2012-01-01 to 2012-09-30	20,361,217	USD	274
2011-07-01 to 2011-09-30	5,375,419	USD	92
2011-01-01 to 2011-09-30	15,949,826	USD	273

Net inventory

Inventory carrying amount after applicable valuation and LIFO reserves. It does not establish realizable selling proceeds or inventory turnover without other inputs.

Period	Value	Unit	Days
At 2012-09-30	56,968	USD
At 2011-12-31	51,174	USD

Gross profit

Revenue less the costs directly attributed to the goods or services sold. It precedes other operating expenses and is not net income.

Period	Value	Unit	Days
2012-07-01 to 2012-09-30	833,817	USD	92
2012-01-01 to 2012-09-30	2,418,874	USD	274
2011-07-01 to 2011-09-30	1,143,054	USD	92
2011-01-01 to 2011-09-30	2,723,631	USD	273

Cost of revenue

Costs attributed to goods produced and sold and services provided during the period. This is not the sum of every operating expense.

Period	Value	Unit	Days
2012-07-01 to 2012-09-30	169,734	USD	92
2012-01-01 to 2012-09-30	273,916	USD	274
2011-07-01 to 2011-09-30	18,516	USD	92
2011-01-01 to 2011-09-30	58,808	USD	273

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

Period	Value	Unit	Days
2012-07-01 to 2012-09-30	4,545,470	USD	92
2012-01-01 to 2012-09-30	13,323,410	USD	274
2011-07-01 to 2011-09-30	3,488,121	USD	92
2011-01-01 to 2011-09-30	9,756,443	USD	273

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

Period	Value	Unit	Days
At 2012-09-30	49,162,758	shares
At 2011-12-31	49,035,788	shares

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

Period	Value	Unit	Days
At 2012-09-30	93,972	USD
At 2011-12-31	93,972	USD

Accumulated other comprehensive income or loss

Cumulative other comprehensive items after tax, such as translation and unrealized hedging or securities effects. These amounts have not passed through net income.

Period	Value	Unit	Days
At 2012-09-30	-197,384	USD
At 2011-12-31	-122,749	USD

Total equity including noncontrolling interests

Equity including the portion attributable to noncontrolling interests. It is larger than or equal to parent stockholders equity and is not market capitalization.

Period	Value	Unit	Days
At 2012-09-30	29,211,595	USD
At 2011-12-31	41,458,181	USD

Gross property, plant and equipment

Cost of property, plant and equipment before accumulated depreciation. Historical cost does not indicate current value or replacement cost.

Period	Value	Unit	Days
At 2012-09-30	2,062,655	USD
At 2011-12-31	1,900,090	USD

Accumulated depreciation on property, plant and equipment

Cumulative depreciation, depletion and amortization recorded against property, plant and equipment. It measures cost allocation to date, not physical wear or market value.

Period	Value	Unit	Days
At 2012-09-30	811,572	USD
At 2011-12-31	552,311	USD

Other noncurrent liabilities

Noncurrent liabilities the filer does not present separately. The composition differs by filer and is described only in the filing.

Period	Value	Unit	Days
At 2012-09-30	235,330	USD
At 2011-12-31	258,620	USD

Prepaid expenses and other current assets

Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.

Period	Value	Unit	Days
At 2012-09-30	1,861,407	USD
At 2011-12-31	2,692,303	USD

Profit or loss including noncontrolling interests

Net income or loss including the portion attributable to noncontrolling interests. It can differ from the net income attributable to the parent that per-share figures use.

Period	Value	Unit	Days
2012-07-01 to 2012-09-30	-5,923,619	USD	92
2012-01-01 to 2012-09-30	-18,153,918	USD	274
2011-07-01 to 2011-09-30	-4,236,619	USD	92
2011-01-01 to 2011-09-30	-12,988,792	USD	273

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

Period	Value	Unit	Days
2012-07-01 to 2012-09-30	2,234,905	USD	92
2012-01-01 to 2012-09-30	7,037,807	USD	274
2011-07-01 to 2011-09-30	1,887,298	USD	92
2011-01-01 to 2011-09-30	6,193,383	USD	273

Depreciation expense

Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.

Period	Value	Unit	Days
2012-01-01 to 2012-09-30	283,637	USD	274
2011-01-01 to 2011-09-30	260,646	USD	273

Amortization of intangible assets

Amortization recognized on finite-lived intangible assets. It follows acquisition accounting and does not indicate the intangibles are losing usefulness at that rate.

Period	Value	Unit	Days
2012-01-01 to 2012-09-30	1,764,382	USD	274
2011-01-01 to 2011-09-30	1,626,476	USD	273

Other nonoperating income or expense

Other income or expense outside operations under this concept. The composition is filer-specific and can include one-time items.

Period	Value	Unit	Days
2012-07-01 to 2012-09-30	22,939	USD	92
2012-01-01 to 2012-09-30	-211,575	USD	274
2011-07-01 to 2011-09-30	-4,254	USD	92
2011-01-01 to 2011-09-30	237,403	USD	273

Change in accounts receivable

The cash flow adjustment for the change in receivables during the period. A positive value under this concept means receivables grew and reduced operating cash flow.

Period	Value	Unit	Days
2012-01-01 to 2012-09-30	459,555	USD	274
2011-01-01 to 2011-09-30	25,272	USD	273

Change in inventories

The cash flow adjustment for the change in inventories during the period. A positive value under this concept means inventory grew and reduced operating cash flow.

Period	Value	Unit	Days
2012-01-01 to 2012-09-30	5,794	USD	274
2011-01-01 to 2011-09-30	-21,154	USD	273

Inspect the source

Entity: Lineage Cell Therapeutics, Inc. / CIK 0000876343
Captured: 2026-09-20T05:01:04.503Z
SEC response SHA-256: de850ac42665e48058d541d948514740e0c9007b61646401dcae831c504c80bf

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python

import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0000876343.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))